Imugene Ltd
OTC:IUGNF

Watchlist Manager
Imugene Ltd Logo
Imugene Ltd
OTC:IUGNF
Watchlist
Price: 0.238 USD -6.08%
Market Cap: $1.8B

Relative Value

There is not enough data to reliably calculate the relative value of IUGNF.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IUGNF Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

IUGNF Competitors Multiples
Imugene Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Imugene Ltd
OTC:IUGNF
101.5m USD 0 -1.5 -1 -1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 746 422.5 -160 391.7 -165 649.1 -163 758.9
US
Abbvie Inc
NYSE:ABBV
395.8B USD 6.5 165.3 16.1 22.8
US
Amgen Inc
NASDAQ:AMGN
187.7B USD 5.1 26.4 18.9 18.9
US
Gilead Sciences Inc
NASDAQ:GILD
175.1B USD 6 21.5 14.6 14.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD 10.3 32.9 24.2 25.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 087.6 -532.7 -682 -663.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD 5.6 17.3 16.5 18.7
AU
CSL Ltd
ASX:CSL
87.1B AUD 3.8 19.8 9.1 11.3
NL
argenx SE
XBRU:ARGX
44B EUR 14.1 33.2 67.2 69.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.8B USD 14.4 1 061.8 143.1 173.5
P/S Multiple
Revenue Growth P/S to Growth
AU
Imugene Ltd
OTC:IUGNF
Average P/S: 3 374 857.6
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 746 422.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
6
4%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.3
10%
1
US
E
Epizyme Inc
F:EPE
2 087.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
14.1
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.4
47%
0.3
P/E Multiple
Earnings Growth PEG
AU
Imugene Ltd
OTC:IUGNF
Average P/E: 172.3
Negative Multiple: -1.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 391.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
165.3
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
21.5
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.9
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
10%
1.7
AU
CSL Ltd
ASX:CSL
19.8
11%
1.8
NL
argenx SE
XBRU:ARGX
33.2
42%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 061.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Imugene Ltd
OTC:IUGNF
Average EV/EBITDA: 38.7
Negative Multiple: -1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 649.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.9
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.6
7%
2.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.2
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -682 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
9.1
8%
1.1
NL
argenx SE
XBRU:ARGX
67.2
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
143.1
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Imugene Ltd
OTC:IUGNF
Average EV/EBIT: 44.3
Negative Multiple: -1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 758.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.9
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.6
13%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.3
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -663.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
13%
1.4
AU
CSL Ltd
ASX:CSL
11.3
11%
1
NL
argenx SE
XBRU:ARGX
69.1
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
173.5
N/A N/A